Aurobindo Pharma Receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid
20 hours agoBusiness
34LENS
3 SourcesGujarat, India
TBNthebalanced.news

Aurobindo Pharma Receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per ml, equivalent to Horizon Therapeutics' Ravicti. The product, indicated for managing urea cycle disorders, will be produced at the company's Unit-III facility and launched immediately. The drug's market size is estimated at $50.2 million for the year ending February 2026. This approval brings Aurobindo's total USFDA ANDA approvals to 579.

Political Bias
0%100%0%
Sentiment
73%
AI analysis of 3 sources · Published under editorial oversight by The Balanced News
Analysed 17 Apr 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 3 sources
● Left 0%● Center 100%● Right 0%

The articles present a straightforward business and regulatory update without political framing. Coverage focuses on Aurobindo Pharma's regulatory milestone and market implications, reflecting a neutral corporate and healthcare industry perspective. There is no evident political viewpoint or partisan framing in the sources.

Sentiment — Positive (73/100)

The tone across the articles is positive and factual, highlighting the company's regulatory success and potential market opportunity. The coverage emphasizes growth and product launch prospects without criticism or controversy, resulting in an overall optimistic but balanced sentiment.

How 3 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
news18Aurobindo Pharma gets USFDA nod for generic glycerol phenylbutyrate oral liquidCenterPositive
businessstandardAurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral LiquidCenterPositive
businessstandardAurobindo Pharma receives USFDA approval for Glycerol Phenylbutyrate Oral LiquidCenterPositive

Coverage timeline

businessstandard broke this story on 17 Apr, 05:48 am. Other outlets followed.

  1. 1
    businessstandard17 Apr, 05:48 am
    Aurobindo Pharma receives USFDA approval for Glycerol Phenylbutyrate Oral Liquid
  2. 2
    businessstandard17 Apr, 06:18 am
    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid
  3. 3
    news1817 Apr, 11:19 am
    Aurobindo Pharma gets USFDA nod for generic glycerol phenylbutyrate oral liquid

Lens Score breakdown

34/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
US Food Drug AdministrationAurobindo PharmaHorizon Therapeutics U.S. Holding LLC

Story context

Category
Business
Location
Gujarat, India
Sources analysed
3
Last analysed
17 Apr 2026
Key entities
Aurobindo PharmaFood and Drug AdministrationHorizon TherapeuticsBioequivalenceUrea cycleAmino acidGlycerolLiquidGlycerol phenylbutyrateAbbreviated New Drug ApplicationProtein (nutrient)Generic drug